Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher Sweeney

Showing results (71-80 of 88) with videos related to

Pageof 9
Sort By:
European Journal of Cancer (Oxford, England : 1990)|February 14, 2023
Risk of residual cancer after complete response following first-line chemotherapy in men with metastatic non-seminomatous germ cell tumour and International Germ Cell Cancer Cooperative Group intermediate/poor prognosis: A multi-institutional retrospective cohort studyLuca Antonelli, Davide Ardizzone, Praful Ravi, et al.
European Urology|March 18, 2014
Effects of cabozantinib on pain and narcotic use in patients with castration-resistant prostate cancer: results from a phase 2 nonrandomized expansion cohortEthan Basch, Karen A Autio, Matthew R Smith, et al.
Lancet (London, England)|July 11, 2021
Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trialChristopher Sweeney, Sergio Bracarda, Cora N Sternberg, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|June 28, 2012
The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysisAndreas Pettersson, Rebecca E Graff, Scott R Bauer, et al.
The Journal of Liquid Biopsy|July 24, 2025
Fragmentomic-based algorithm to computationally predict tumor-somatic, germline, and clonal hematopoiesis variant origin in liquid biopsyDerek W Brown, Daokun Sun, Alexander D Fine, et al.
Clinical Genitourinary Cancer|August 31, 2024
Outcomes of First-Line Abiraterone Acetate or Enzalutamide for Older Adults With Metastatic Castration-Resistant Prostate Cancer According to Use of Upfront Docetaxel for Metastatic Castration-Sensitive Prostate Cancer in an International Multicenter Registry: A SPARTACUSS-Meet-URO 26 StudyGiuseppe Fotia, Calogero Saieva, Richard Lee-Ying, et al.
Clinical Genitourinary Cancer|October 26, 2024
Docetaxel Versus Androgen-Receptor Signaling Inhibitors (ARSI) as Second-Line Therapy After Failure of First-Line Alternative ARSI for the Elderly ≥ 75 Years Old With Metastatic Castration-Resistant Prostate Cancer (mCRPC): A SPARTACUSS-Meet-URO 26 Real-World StudyAnna Patrikidou, Calogero Saieva, Richard Lee-Ying, et al.
European Urology Oncology|April 3, 2024
Multi-institutional Analysis of Metastasis-directed Therapy with or Without Androgen Deprivation Therapy in Oligometastatic Castration-sensitive Prostate CancerMatthew P Deek, Philip Sutera, Yuezhou Jing, et al.
European Urology|May 12, 2023
Clinical and Genomic Differences Between Advanced Molecular Imaging-detected and Conventional Imaging-detected Metachronous Oligometastatic Castration-sensitive Prostate CancerPhilip Sutera, Yang Song, Kim Van der Eecken, et al.
Science Translational Medicine|April 12, 2012
Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profileJeffrey Hrkach, Daniel Von Hoff, Mir Mukkaram Ali, et al.
Pageof 9

Showing results (71-80 of 88) with videos related to

Sort By:
Pageof 9
European Journal of Cancer (Oxford, England : 1990)|February 14, 2023
Risk of residual cancer after complete response following first-line chemotherapy in men with metastatic non-seminomatous germ cell tumour and International Germ Cell Cancer Cooperative Group intermediate/poor prognosis: A multi-institutional retrospective cohort studyLuca Antonelli, Davide Ardizzone, Praful Ravi, et al.
European Urology|March 18, 2014
Effects of cabozantinib on pain and narcotic use in patients with castration-resistant prostate cancer: results from a phase 2 nonrandomized expansion cohortEthan Basch, Karen A Autio, Matthew R Smith, et al.
Lancet (London, England)|July 11, 2021
Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trialChristopher Sweeney, Sergio Bracarda, Cora N Sternberg, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|June 28, 2012
The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysisAndreas Pettersson, Rebecca E Graff, Scott R Bauer, et al.
The Journal of Liquid Biopsy|July 24, 2025
Fragmentomic-based algorithm to computationally predict tumor-somatic, germline, and clonal hematopoiesis variant origin in liquid biopsyDerek W Brown, Daokun Sun, Alexander D Fine, et al.
Clinical Genitourinary Cancer|August 31, 2024
Outcomes of First-Line Abiraterone Acetate or Enzalutamide for Older Adults With Metastatic Castration-Resistant Prostate Cancer According to Use of Upfront Docetaxel for Metastatic Castration-Sensitive Prostate Cancer in an International Multicenter Registry: A SPARTACUSS-Meet-URO 26 StudyGiuseppe Fotia, Calogero Saieva, Richard Lee-Ying, et al.
Clinical Genitourinary Cancer|October 26, 2024
Docetaxel Versus Androgen-Receptor Signaling Inhibitors (ARSI) as Second-Line Therapy After Failure of First-Line Alternative ARSI for the Elderly ≥ 75 Years Old With Metastatic Castration-Resistant Prostate Cancer (mCRPC): A SPARTACUSS-Meet-URO 26 Real-World StudyAnna Patrikidou, Calogero Saieva, Richard Lee-Ying, et al.
European Urology Oncology|April 3, 2024
Multi-institutional Analysis of Metastasis-directed Therapy with or Without Androgen Deprivation Therapy in Oligometastatic Castration-sensitive Prostate CancerMatthew P Deek, Philip Sutera, Yuezhou Jing, et al.
European Urology|May 12, 2023
Clinical and Genomic Differences Between Advanced Molecular Imaging-detected and Conventional Imaging-detected Metachronous Oligometastatic Castration-sensitive Prostate CancerPhilip Sutera, Yang Song, Kim Van der Eecken, et al.
Science Translational Medicine|April 12, 2012
Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profileJeffrey Hrkach, Daniel Von Hoff, Mir Mukkaram Ali, et al.
Pageof 9